Venock, founded as a medical technology startup, focuses on developing innovative solutions for large bore vascular closure following transcatheter cardiovascular therapies. The company's core mission is to enhance patient outcomes and procedural efficiency in cardiovascular treatments. Venock's primary product addresses the need for effective closure of large venous access sites, which are critical in procedures such as ASD closure, mitral valve repair, and pulmonary embolectomy. Their market focus includes hospitals and cardiovascular treatment centers globally.

Notable achievements include winning the CSI Innovation Award, underscoring their impact and recognition within the medtech industry. The company's innovative approach has garnered attention from key stakeholders in the medical community, positioning Venock as a significant player in improving cardiovascular therapeutic procedures. Through their specialized technology, Venock aims to reduce complications and recovery times for patients undergoing complex cardiovascular interventions.